checkAd

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced today that it will effect a 1-for-50 reverse stock split of its outstanding common stock. Subject to NYSE American (“NYSE” or the “Exchange”) approval, the Company anticipates that trading will resume on the NYSE American on an as-adjusted basis as of the commencement of trading on Wednesday, November 9, 2022. As previously announced, the trading of the Company’s shares of common stock was halted by the Exchange due to the low trading price of the Company’s shares of common stock on November 1, 2022. Although not anticipated by the Company, the Exchange could maintain the trading halt. The Exchange could also suspend trading and move to delist the Company’s common stock if the price per share post-split does not meet the requirements of Section 1003(f)(v) of the NYSE American Company Guide.

The Company expects Timber’s common stock to resume trading on the the NYSE American LLC (“NYSE American”) under the symbol “TMBR” and under a new CUSIP number, 887080208. As a result of the reverse stock split, every 50 pre-split shares of common stock outstanding will become one share of common stock. The par value of the Company’s common stock will remain unchanged at $0.001 per share after the reverse stock split. The reverse stock split will not change the authorized number of shares of the Company’s common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment based on the average closing price of the Company’s common stock on the five (5) consecutive trading days leading up to the effective date of the reverse split. The reverse split will also apply to common stock issuable upon the exercise of Timber’s outstanding warrants and stock options, with a proportionate adjustment to the exercise prices thereof, and under the Company’s equity incentive plans.

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: globenewswire
 |  222   |   |   

Schreibe Deinen Kommentar

Disclaimer

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) - via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of …

Nachrichten des Autors

268 Leser
248 Leser
240 Leser
232 Leser
228 Leser
220 Leser
220 Leser
212 Leser
212 Leser
208 Leser
516 Leser
472 Leser
456 Leser
420 Leser
412 Leser
408 Leser
396 Leser
368 Leser
368 Leser
364 Leser
1668 Leser
1044 Leser
900 Leser
856 Leser
828 Leser
820 Leser
800 Leser
764 Leser
728 Leser
712 Leser
10533 Leser
4344 Leser
3424 Leser
2744 Leser
2246 Leser
2214 Leser
2077 Leser
2052 Leser
2037 Leser
1823 Leser